Co-administered tetracyclines and fluoroquinolones

Co-administered tetracyclines and fluoroquinolones does not refer to a single biological target but rather a clinical drug combination involving two distinct classes of antibiotics. Tetracyclines, such as doxycycline, are bacteriostatic agents that inhibit protein synthesis by binding to the 30S ribosomal subunit (StatPearls, 2023). Fluoroquinolones, such as ciprofloxacin, are bactericidal agents that target bacterial DNA gyrase and topoisomerase IV to disrupt DNA replication (NIH, 2022). This combination is sometimes employed in the treatment of complex or polymicrobial infections, including pelvic inflammatory disease and certain community-acquired pneumonias, to ensure coverage of Gram-positive, Gram-negative, and atypical pathogens. However, the co-administration is a subject of pharmacological debate due to the potential for antagonism, as bacteriostatic drugs can sometimes interfere with the efficacy of bactericidal drugs that require active cell division to function. Clinicians must also monitor for additive side effects, such as severe gastrointestinal distress and increased risk of photosensitivity.

Other names

Tetracycline-Fluoroquinolone combination therapyTetracycline and Fluoroquinolone co-therapyCombined bacteriostatic and bactericidal antibiotic therapy

Tetracyclines bind to the 30S ribosomal subunit to inhibit protein synthesis by blocking the attachment of aminoacyl-tRNA to the A site (StatPearls, 2023). Fluoroquinolones inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, which are essential for DNA replication, transcription, and repair (PubMed, 2021).